Alain Munoz joins Hybrigenics board
This article was originally published in Scrip
Hybrigenics, a Paris-based biopharma developing treatments for proliferative diseases and specialised protein interactions, has appointed Dr Alain Munoz to its board as a non-executive independent director replacing Dr Bernhard Ehmer, president of ImClone Systems. Dr Munoz has over 20 years' experience at senior management level with companies such as Sanofi and Fournier.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.